[go: up one dir, main page]

AR017079A1 - Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso. - Google Patents

Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.

Info

Publication number
AR017079A1
AR017079A1 ARP980104487A ARP980104487A AR017079A1 AR 017079 A1 AR017079 A1 AR 017079A1 AR P980104487 A ARP980104487 A AR P980104487A AR P980104487 A ARP980104487 A AR P980104487A AR 017079 A1 AR017079 A1 AR 017079A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
procedure
same
treatment method
Prior art date
Application number
ARP980104487A
Other languages
English (en)
Original Assignee
West Christopher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by West Christopher filed Critical West Christopher
Publication of AR017079A1 publication Critical patent/AR017079A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composicion farmacéutica, un proceso para la preparacion de la misma, un método de tratamiento y su uso, donde dicha composicion farmacéutica comprendemicropartículas poliméricas que incluyen una droga, preferentemente olanzapina, y un ácido graso, cuya composicion puede ser adaptada para proveer unavelocidad de liberacion de droga que es aproximadamente lineal en el tiempo, y que tiene un efecto de liberacion repentina o explosiva insignificante.
ARP980104487A 1997-09-09 1998-09-09 Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso. AR017079A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9718986.4A GB9718986D0 (en) 1997-09-09 1997-09-09 Controlled release microsphere delivery system

Publications (1)

Publication Number Publication Date
AR017079A1 true AR017079A1 (es) 2001-08-22

Family

ID=10818687

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980104487A AR017079A1 (es) 1997-09-09 1998-09-09 Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.

Country Status (10)

Country Link
EP (1) EP1011680A2 (es)
JP (1) JP2001515862A (es)
AR (1) AR017079A1 (es)
AU (1) AU745511B2 (es)
CA (1) CA2302762A1 (es)
GB (1) GB9718986D0 (es)
NO (1) NO20001219L (es)
NZ (1) NZ502710A (es)
WO (1) WO1999012549A2 (es)
ZA (1) ZA987762B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
US6331317B1 (en) 1999-11-12 2001-12-18 Alkermes Controlled Therapeutics Ii Inc. Apparatus and method for preparing microparticles
US6705757B2 (en) 1999-11-12 2004-03-16 Alkermes Controlled Therapeutics, Inc. Ii Method and apparatus for preparing microparticles using in-line solvent extraction
US6495166B1 (en) 1999-11-12 2002-12-17 Alkermes Controlled Therapeutics Inc. Apparatus and method for preparing microparticles using in-line solvent extraction
ES2169980B1 (es) * 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US6824822B2 (en) 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US6471995B1 (en) 2000-09-27 2002-10-29 Alkermes Controlled Therapeutics, Inc. Ii Apparatus and method for preparing microparticles using liquid-liquid extraction
US20020114843A1 (en) 2000-12-27 2002-08-22 Ramstack J. Michael Preparation of microparticles having improved flowability
CN1662260B (zh) 2002-06-25 2010-04-28 武田药品工业株式会社 缓释组合物的制备方法
JP2006506397A (ja) * 2002-10-31 2006-02-23 ファイザー・プロダクツ・インク 固体及び半固体高分子イオン・コンジュゲート
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
EA200601904A1 (ru) 2004-04-15 2007-02-27 Алкермес, Инк. Система отсроченного высвобождения лекарственного средства на основе полимеров
AU2005278894A1 (en) 2004-08-31 2006-03-09 Pfizer Products Inc. Pharmaceutical dosage forms comprising a low-solubility drug and a polymer
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
JP5048773B2 (ja) 2006-08-09 2012-10-17 インターシア セラピューティクス，インコーポレイティド 浸透圧式デリバリーシステム及びピストンアセンブリー
RU2009116933A (ru) * 2006-10-05 2010-11-10 Панацея Биотек Лтд. (In) Новые депо-композиции для инъекций и способ изготовления указанных композиций
GEP20125597B (en) 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
NZ580447A (en) 2007-04-23 2011-06-30 Intarcia Therapeutics Inc Suspension formulations of insulinotropic peptides and uses thereof
NO2170279T3 (es) 2007-07-31 2018-05-26
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
RU2753280C2 (ru) 2009-09-28 2021-08-12 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
CN103458895B (zh) * 2010-11-25 2014-07-09 山东绿叶制药有限公司 罗替戈汀、其衍生物或罗替戈汀或其衍生物药用盐的组合物
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
JO3410B1 (ar) 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
CN109310743A (zh) 2016-05-16 2019-02-05 因塔西亚制药公司 胰高血糖素受体选择性多肽及其使用方法
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
WO2018172850A1 (en) 2017-03-20 2018-09-27 Teva Pharmaceuticals International Gmbh Sustained release olanzapine formulaitons
KR102045721B1 (ko) * 2019-03-27 2019-11-18 주식회사 씨트리 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4384975A (en) * 1980-06-13 1983-05-24 Sandoz, Inc. Process for preparation of microspheres
US4389330A (en) * 1980-10-06 1983-06-21 Stolle Research And Development Corporation Microencapsulation process
GB9009229D0 (en) * 1990-04-25 1990-06-20 Lilly Industries Ltd Pharmaceutical compounds
ATE188375T1 (de) * 1992-11-17 2000-01-15 Yoshitomi Pharmaceutical Ein antipsychotikum enthaltende mikrokugel zur verzögerten freisetzung und verfahren für ihre herstellung
IL117612A0 (en) * 1995-03-24 1996-07-23 Lilly Co Eli Granule formulation for olanzapine

Also Published As

Publication number Publication date
WO1999012549A3 (en) 1999-05-06
ZA987762B (en) 2000-02-28
NO20001219D0 (no) 2000-03-09
JP2001515862A (ja) 2001-09-25
WO1999012549A2 (en) 1999-03-18
AU8992598A (en) 1999-03-29
EP1011680A2 (en) 2000-06-28
GB9718986D0 (en) 1997-11-12
NZ502710A (en) 2001-09-28
NO20001219L (no) 2000-03-09
CA2302762A1 (en) 1999-03-18
AU745511B2 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AR017079A1 (es) Una composicion farmaceutica, un procedimiento para la preparacion de la misma, un metodo de tratamiento y su uso.
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
ES2148198T3 (es) Procedimiento de trituracion de sustancias farmaceuticas.
ES2177022T3 (es) Un itraconazol que exhibe una solubilidad mejorada, un metodo para preparar el mismo y una composicion farmaceutica para administracion oral que comprende el mismo.
MX9201782A (es) Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
DK0695172T3 (da) Fast præparat med hurtig frigørelse, dets fremstilling og dets anvendelse
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
DE59601880D1 (de) Verfahren zur herstellung hydrophiler oder teilweise hydrophiler, anorganischer aerogele
CO5150154A1 (es) Composicion de sustrato y metodo para usarlo para el secuestro de irritantes de la piel
AR004483A1 (es) Compuestos para uso en terapia que comprenden un residuo de 1,3-propano diol como agente enlazante entre el residuo de ácido graso y un residuo bioactivo, usos de dichos compuestos y medicamentos , alimentos y formulaciones para el cuidado o tratamiento de la piel que comprenden a dichos compuestos
DE3769379D1 (de) Entzuendungshemmende wirkstoffe, pharmazeutische zusammensetzungen und verfahren zur bekaempfung von entzuendungen.
BR9510302A (pt) Forma de dosagem farmacêutical de liberação controlada método para tratamento sintomático da tosse método para preparar uma forma de dosagem farmacêutica de liberação controlada composição para uso no tratamento sintomático da tosse e aplicação de uma forma dosagem de moguisteina de liberação controlada
MX9204268A (es) Una composicion para la liberacion prolongada y controlada de substancias medicamentosas y un proceso para preparar la misma.
MX9605419A (es) Formas de dosificacion de liberacion controlada de azitromicina.
MX9102353A (es) N,o-sulfados de heparosanos, su procedimiento de preparacion y las composiciones farmaceuticas que contienen.
SV2004001556A (es) Preparaciones acidas de insulina con establidad mejorada
EE9700145A (et) Tsükloalkaanpüridiinid, nende valmistamismeetod, kasutamine ravimite tootmiseks ja nimetatud ühendeid sisaldavad ravimid
ES2137372T3 (es) Solucion antifungica para las uñas.
DE69511117D1 (de) Verkapselte active materialien und verfahren zur ihrer herstellung
EP0802787A4 (en) VECTOR FOR DELIVERY OF BIO-EFFECTIVE SUBSTANCES WITH GELLIFICATION -i (IN SITU) AND METHOD OF USE
DE4495520T1 (de) Verfahren und pharmazeutische Zusammensetzung zum zielgerichten Anwenden von Wirkstoffen
ES2132556T3 (es) Nuevo derivado de benzo-tiadiazina, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen.
TR199801104T2 (xx) Ereksiyon disfonksiyonunun tedavisinde kullan�lan PGE-1 i�eren liyofilize lipozomlar.
ES2174533T3 (es) Uso de una mezcla de un diol y un acido alfa-hidroxi para el tratamiento de enfermedades de la piel hiperqueratoticas.
DE59708495D1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung